Madrigal Pharmaceuticals (MDGL) Stock Price & Analysis

MDGL$427.39+2.18 +0.51%
BiotechnologyGrowth Stock
Compare
Market cap$9.93BEnterprise value$9.09BRevenue (TTM)$1.43BMarket position—

Score

65
Bullish
Value
50
Quality
44
Growth
100

AI Analysis

Snapshot

Madrigal Pharmaceuticals is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 65/100) in Biotechnology. Under the hood: revenue compounding ~432% annually over recent years. Street targets still imply ~60% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

50
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

44
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Madrigal Pharmaceuticals, Inc. (MDGL) last printed $427.39. Equity value is $9.93B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$180.13M$958.4M

About

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals (MDGL) Stock Price & Analysis

MDGL price $427.39 +2.18 +0.51%

Ticker
MDGL
Price
$427.39
Change
+2.18 +0.51%
Market cap
$9.93B
Forward P/E
87.44
Dividend yield
0.00%
Beta
-1.00
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
65
Value
50
Quality
44
Growth
100

Stocklytics score rationale: value 50, quality 44, growth 100.

AI Score 45. Madrigal Pharmaceuticals, Inc. has a high price of $396.32 and a market cap of $9.16 billion, but it is in the clinical development phase with negative margins, including a net profit margin of -0.1089

Insights · Forecast · Financials · Learn

Stocklytics home · Screener